Company profile
Deltadot Limited
deltaDOT - deltaDOT Ltd
Deltadot Limited is a UK company with status active founded in 2000 based in London.
Latest accounts
Financial period: 1 Jan 2024 to 31 Dec 2024
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation Statement With Updates
Confirmation-statementCS01 | Transaction MzUxMjkyNjAwNmFkaXF6a2N4
Published 27 Mar 2026 08:15
Appoint Person Director Company With Name Date
OfficersAP01 | Transaction MzUxMjgxNDgxM2FkaXF6a2N4
Published 26 Mar 2026 17:50
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzUxMjgxMzI0MmFkaXF6a2N4
Published 26 Mar 2026 17:30
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQzNzIyNDk5N2FkaXF6a2N4
Published 25 Sep 2024 04:06
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Development of rapid and low-cost tool for biopharmaceutical formulation screening
1 Sep 2013 to 30 Nov 2014
The project will bring an enabling platform technology that has been previously developed in 2012 TSB-funded feasibility study, to demonstrator stage. The demonstrator will address an unmet need in biopharmaceutical manufacturing industry, namely a cost-effective, user-friendly, automated system that will allow rapid screening for protein interaction lead...
Rapid low cost formulation screening for protein self-interaction based on High Performance Capillary Electrophoresis
1 Aug 2012 to 30 Nov 2012
The advance in protein-based biopharmaceuticals represents the most innovative and lucrative development in the pharmaceutical industry. Treatment with mAbs has evolved from former high mortality diseases like cancer into modern day chronic illness, including Alzheimer’s disease, lupus, diabetes and chronic pain. With the increased need for biopharmaceuti...